Trial Title:
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
NCT ID:
NCT05886634
Condition:
Dedifferentiated Liposarcoma
Soft Tissue Sarcoma
Sarcoma,Soft Tissue
Sarcoma
Recurrent Dedifferentiated Liposarcoma
Unresectable Dedifferentiated Liposarcoma
Metastatic Dedifferentiated Liposarcoma
Conditions: Official terms:
Sarcoma
Liposarcoma
Conditions: Keywords:
Dedifferentiated Liposarcoma
Recurrent Dedifferentiated Liposarcoma
Unresectable Dedifferentiated Liposarcoma
Metastatic Dedifferentiated Liposarcoma
Soft Tissue Sarcoma
Sarcoma, Soft Tissue
Sarcoma
DDLPS
Memorial Sloan Kettering Cancer Center
22-277
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Etrumadenant
Description:
Will be administered PO daily for 24 weeks
Arm group label:
Participants With Dedifferentiated Liposarcoma/DDLPS
Intervention type:
Drug
Intervention name:
Zimberelimab
Description:
Will be administered IV every 2 weeks for 24 weeks
Arm group label:
Participants With Dedifferentiated Liposarcoma/DDLPS
Summary:
Participants will have a diagnosis of dedifferentiated liposarcoma (DDLS) that has spread
beyond its original location (advanced). In addition, their DDLS either has come back
after treatment (recurrent), has spread to different parts of your body (metastatic), or
is unable to be removed surgically (unresectable). The purpose of this study is to find
out whether the combination of etrumadenant and zimberelimab is an effective treatment
for people with advanced DDLS.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Diagnosis of recurrent, unresectable, or metastatic DDLPS
- The definition of recurrent disease is a patient with a primary tumor that has
been successfully resected, but has recurred after primary surgery
- Any number of prior systemic therapies will be allowed
- Age ≥ 18 years at the time of informed consent
- Willing and able to provide written informed consent/assent for the trial
- Willing to comply with treatment protocol
- Adequate performance status: Eastern Cooperative Oncology Group (ECOG) Performance
Status 0 or 1/Karnofsky Performance Status (KPS) 70-100%
- Presence of measurable disease per RECIST v1.1
o Target lesions must not be chosen from a previously irradiated field unless there
has been radiographically and/or pathologically documented tumor progression
- QTc ≤ 480 msec using Fredericia's QT correction formula
- Adequate organ function determined within 2 weeks of treatment initiation, defined
as follows:
- Hemoglobin ≥ 9.0 g/dL
- Absolute neutrophil count ≥ 1,500/mm3 (1.0 x 109/L)
- Platelet count ≥ 75,000/mm3 (50 x 109/L)
- Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) OR direct bilirubin ≤ ULN
for a patient with total bilirubin level > 1.5 x ULN
- Aspartate aminotransferase (AST) ≤ 2.5 x ULN OR ≤ 5 x ULN for patients with
liver metastases
- Alanine aminotransferase (ALT) ≤ 2.5 x ULN OR ≤ 5 x ULN for patients with liver
metastases
- Alkaline phosphatase < 5 x ULN
- Serum creatinine ≤ 1.5 x ULN or a measured or calculated creatinine clearancea
≥ 60 mL/min for a patient with creatinine levels > 1.5 x institutional ULN
(Note: Creatinine clearance need not be determined if the baseline serum
creatinine is within normal limits. GFR can also be used in place of creatinine
or CrCl)
- International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 X ULN
unless patient is receiving anticoagulant therapy as long as PT or PTT is
within therapeutic range of intended use of anticoagulants
- Activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN unless subject is
receiving anticoagulant therapy as long as PT and PTT is within therapeutic
range of intended use of anticoagulants
- For female patients of childbearing potential, negative serum pregnancy test at
screening visit and within 72 h prior to the first dose of study medication
aCreatinine clearance should be calculated per institutional standard.
Contraception Requirements
Female participants of reproductive potential and male participants with female partners
of reproductive potential are required to use highly effective contraceptive measures
from the first dose of study treatment until 30 days after the last dose of etrumadenant
or 90 days after the last dose of zimberelimab, whichever is longer.
- A female participant (or female partner of a male participant) is considered fertile
following menarche and until becoming post-menopausal unless permanently sterile.
- Permanent sterilization methods include hysterectomy, bilateral salpingectomy
and bilateral oophorectomy.
- A postmenopausal state is defined as no menses for 12 months without an
alternative medical cause. A high follicle-stimulating hormone (FSH) level in
the postmenopausal range may be used to confirm a post-menopausal state in
women not using hormonal contraception or hormonal replacement therapy.
However, in the absence of 12 months of amenorrhea, a single FSH measurement is
insufficient.
- A man is considered fertile after puberty unless permanently sterile by bilateral
orchidectomy
Highly effective contraception is defined as use of one or more methods that result in a
low failure rate (i.e., less than 1%). Highly effective contraceptive measures include:
- Combined (estrogen and progestogen containing) hormonal contraception associated
with inhibition of ovulation: oral, intravaginal, transdermal
- Progestogen only hormonal contraception associated with inhibition of ovulation:
oral, injectable, implantable
- Intrauterine device
- Intrauterine hormone-releasing system in combination with a barrier method
(preferably male condom)
- Surgical sterilization
- Female participant or female partner of the male participant has undergone
bilateral tubal ligation
- Male participant is vasectomized (with documented medical confirmation of
surgical success) and is the sole sexual partner of a female with reproductive
potential
- Complete sexual abstinence defined as refraining from heterosexual intercourse
during the entire period of risk associated with study treatment. The reliability of
sexual abstinence needs to be evaluated in relation to the duration of the clinical
trial and the preferred and usual lifestyle of the participant
To ensure proper birth control, female participants who use hormonal contraception should
use an efficient barrier contraceptive (condom plus spermicide). Additionally, male
participants, when having sexual intercourse with a female of reproductive potential,
should use an efficient barrier contraceptive (condom plus spermicide); the respective
partner should also use an additional efficient contraceptive method (e.g., oral pills,
intrauterine device, or diaphragm, and spermicide).
Exclusion Criteria:
Patients who fulfil any of the following criteria are not eligible for admission to the
study:
- Prior treatment with systemic PD-1 or PD-L1 inhibitor
- Prior treatment with an agent targeting the adenosine pathway
- Have a concurrent unrelated malignancy that requires active treatment
o Patients with concurrent malignancies of a different tumor whose natural history
or treatment will likely not interfere with the safety or efficacy assessment of the
investigational drug will be eligible
- Uncontrolled intercurrent illness including active infection requiring systemic
therapy or symptomatic congestive heart failure within the past 6 months
- Has known active central nervous system (CNS) metastases
- Patients with previously treated brain metastases may participate provided they
are stable (without evidence of progression by imaging for at least 4 weeks
prior to study Day 1 and return to baseline of neurologic symptoms), and have
no evidence of new or enlarging brain metastases. This exception does not
include sarcomatous meningitis, which is excluded regardless of clinical
stability.
- Patients must be on a stable or decreasing corticosteroid dose at the time of
study entry; patients who require escalating doses of corticosteroids for the
treatment of CNS metastases will be excluded.
- Shows evidence of clinically significant immunosuppression such as the following:
- Primary immunodeficiency state such as Severe Combined Immunodeficiency Disease
- Concurrent opportunistic infection
- Receiving systemic immunosuppressive therapy (> 2 weeks) including oral steroid
doses > 10 mg/day of prednisone or equivalent within 14 days prior to
enrollment. However, in the setting of non-immune mediated indications for use,
chronic/active low dose steroid use may be permitted at the discretion of the
principal investigator.
- Has a known infection with HIV AND
- CD4+ T-cell (CD4+) counts < 350 cells/uL
- An opportunistic infection within the prior 12 months
- Has a known active infection with hepatitis B or hepatitis C
- Chronic carriers of HBV infection (HBsAg-positive, undetectable or low HBV DNA,
and normal ALT) or individuals who have serologic evidence of a resolved prior
HBV infection (i.e., HBsAg-negative and anti-HBc-positive) may be eligible if
suppressive antiviral therapy can be safely administered.
- Patients who have completed curative antiviral treatment for HCV and have a
viral load below the limit of quantification will be eligible (e.g. a patient
who is HCV Ab positive but HCV RNA negative due to prior treatment or natural
resolution)
- Has a known history of active tuberculosis infection
- Has history or evidence of symptomatic autoimmune disease (e.g., pneumonitis,
glomerulonephritis, vasculitis, or other), or history of active autoimmune disease
that has required systemic treatment (i.e., use of corticosteroids,
immunosuppressive drugs or biological agents used for treatment of autoimmune
diseases) in the past 2 years.
Replacement therapy (e.g., thyroxine for hypothyroidism, insulin for diabetes or
physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is
not considered a form of systemic treatment for autoimmune disease.
- For female subjects, is pregnant or breast-feeding, or planning to become pregnant
- For male subjects, is planning to father a child within the projected duration of
the trial, starting with the pre-screening or screening visit, during study
treatment and through 4 months after the last cycle of treatment
- For patients of childbearing potential, is unwilling to use acceptable method(s) of
effective contraception during study treatment and through 4 months after the last
cycle of treatment. (Women not of childbearing potential are defined as:
post-menopausal [age > 55 years with cessation of menses for 12 or more months or
less than 55 years but not spontaneous menses for at least 2 years or less than 55
years and spontaneous menses within the past 1 year, but currently amenorrhoeic
(e.g., spontaneous or secondary to hysterectomy), and with postmenopausal
gonadotropin levels (luteinizing hormone and follicle-stimulating hormone levels >
40 IU/L) or postmenopausal estradiol levels (< 5 ng/dL) or according to the
definition of "postmenopausal range" for the laboratory involved] or who have had a
hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.)
- Underwent prior chemotherapy, radiotherapy, biological cancer therapy, targeted
small molecule therapy, or major surgery within 4 weeks (or 5 half-lives, whichever
is shorter) prior to study Day 1 or has not recovered (i.e., to CTCAE ≤ grade 1 or
at baseline) from adverse events due to previously administered therapy. Patients
with ≤ grade 2 neuropathy and alopecia are an exception and may qualify for the
study. If patients received major surgery, they must have recovered adequately prior
to starting therapy.
- Is currently participating and receiving study therapy with another investigational
device or study drug or has participated in a study of an investigational agent and
received study therapy or used an investigational device within 4 weeks (or 5
half-lives, whichever is shorter) of the first dose of treatment
- Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial
- Prior organ transplantation, including allogeneic stem-cell transplant
- Due to the potential risk for drug-drug interactions with etrumadenant, participants
must not have had:
- Treatment with known BCRP substrates with a narrow therapeutic window,
administered orally (e.g., prazosin, rosuvastatin) within 4 weeks or 5
half-lives of the drug (whichever is shorter) prior to initiation of and
throughout study treatment
- Treatment with known P-gp substrates with a narrow therapeutic window,
administered orally (e.g., digoxin) within 4 weeks or 5 half-lives of the drug
(whichever is shorter) prior to initiation of study treatment
- Treatment with known strong CYP3A4 inducers (e.g., rifampin, phenytoin,
carbamazepine, phenobarbital, and St. John's Wort) and strong CYP3A4 inhibitors
(e.g., clarithromycin, grapefruit juice, itraconazole, ketoconazole,
posaconazole, telithromycin, and voriconazole) within 4 weeks or 5 half lives
of the drug (whichever is shorter) prior to initiation of study treatment
- Refer to the following for more examples of relevant substrates, inhibitors,
and inducers with the potential for drug-drug interactions with etrumadenant:
https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-
interactions-table-substrates-inhibitors-and-inducers
- Any gastrointestinal condition that would preclude the use of oral medications
(e.g., difficulty swallowing, nausea, vomiting, or malabsorption)
- History of severe allergic reactions to chimeric or humanized antibodies or fusion
protein
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Address:
City:
Basking Ridge
Zip:
07920
Country:
United States
Status:
Recruiting
Contact:
Last name:
Evan Rosenbaum, MD
Phone:
646-888-4159
Email:
zzPDL_MED_Sarcoma_Clinical_Trials@mskcc.org
Facility:
Name:
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Address:
City:
Middletown
Zip:
07748
Country:
United States
Status:
Recruiting
Contact:
Last name:
Evan Rosenbaum, MD
Phone:
646-888-4159
Email:
zzPDL_MED_Sarcoma_Clinical_Trials@mskcc.org
Facility:
Name:
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Address:
City:
Montvale
Zip:
07645
Country:
United States
Status:
Recruiting
Contact:
Last name:
Evan Rosenbaum, MD
Phone:
646-888-4159
Email:
zzPDL_MED_Sarcoma_Clinical_Trials@mskcc.org
Facility:
Name:
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
Address:
City:
Commack
Zip:
11725
Country:
United States
Status:
Recruiting
Contact:
Last name:
Evan Rosenbaum, MD
Phone:
646-888-4159
Email:
zzPDL_MED_Sarcoma_Clinical_Trials@mskcc.org
Facility:
Name:
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Address:
City:
Harrison
Zip:
10604
Country:
United States
Status:
Recruiting
Contact:
Last name:
Evan Rosenbaum, MD
Phone:
646-888-4159
Email:
zzPDL_MED_Sarcoma_Clinical_Trials@mskcc.org
Facility:
Name:
Memorial Sloan Kettering Cancer Center
Address:
City:
New York
Zip:
10065
Country:
United States
Status:
Recruiting
Contact:
Last name:
Evan Rosenbaum, MD
Phone:
646-888-4159
Email:
zzPDL_MED_Sarcoma_Clinical_Trials@mskcc.org
Contact backup:
Last name:
William Tap, MD
Phone:
646-888-4163
Facility:
Name:
Memorial Sloan Kettering Nassau (Limited protocol activities)
Address:
City:
Rockville Centre
Zip:
11553
Country:
United States
Status:
Recruiting
Contact:
Last name:
Evan Rosenbaum, MD
Phone:
646-888-4159
Email:
zzPDL_MED_Sarcoma_Clinical_Trials@mskcc.org
Start date:
May 23, 2023
Completion date:
May 23, 2027
Lead sponsor:
Agency:
Memorial Sloan Kettering Cancer Center
Agency class:
Other
Source:
Memorial Sloan Kettering Cancer Center
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05886634
